Inhibition of cell proliferation

Patent metadata

Field	Value
Publication number	US-9656953-B2
Application number	US-201414171273-A
Country	US
Kind code	B2
Filing date	Feb 3, 2014
Priority date	Nov 22, 2005
Publication date	May 23, 2017
Grant date	May 23, 2017

Abstract

The disclosed modulators of Rb:Raf-1 interactions are potent, selective disruptors of Rb:Raf-1 binding, with IC 50 values ranging from 80 nM to 500 nM. Further, these compounds are surprisingly effective in inhibiting a wide variety of cancer cells, including osteosarcoma, epithelial lung carcinoma, non-small cell lung carcinoma, three different pancreatic cancer cell lines, two different glioblastoma cell lines, metastatic breast cancer, melanoma, and prostate cancer. Moreover, the disclosed compounds effectively disrupt angiogenesis and significantly inhibited tumors in nude mice derived from human epithelial lung carcinoma tumors. Accordingly, the disclosed compounds, pharmaceutical compositions comprising the compounds, methods of inhibiting cell proliferation, methods of treating subjects with cancer, and methods of preparing the disclosed compounds are provided.

First claim

What is claimed is:

1. A compound selected from the group consisting of the following compounds and pharmaceutically acceptable salts thereof:

2. A pharmaceutical composition comprising the compound or pharmaceutically acceptable salt thereof of claim 1 .

3. A pharmaceutical composition comprising the compound or pharmaceutically acceptable salt thereof of claim 1 , wherein the compound is the following compound:

4. A method of treating or ameliorating a cell proliferation disorder, comprising administering to a subject in need of such treatment an effective amount of a compound or pharmaceutically acceptable salt thereof according to claim 1 .

5. The method of claim 4 , wherein the treatment comprises contacting the proliferating cells of the cell proliferation disorder with the compound or pharmaceutically acceptable salt thereof.

6. The method of claim 4 , wherein the regulation of proliferation of cells in the cell proliferation disorder is mediated by at least one protein selected from the group consisting of retinoblastoma tumor suppressor protein and serine threonine kinase Raf 1.

7. The method of claim 4 , wherein the cell proliferation disorder is a cancer.

8. The method of claim 4 , wherein the cell proliferation disorder is a non-cancerous cell proliferation disorder.

9. The method of claim 4 , wherein the cell proliferation disorder is a cancer selected from the group consisting of fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteogenic sarcoma, chordoma, angiosarcoma, endotheliosarcoma, lymphangiosarcoma, lymphangioendotheliosarcoma, synovioma, mesothelioma, Ewing's tumor, leiomyosarcoma, rhabdomyosarcoma, colon carcinoma, pancreatic cancer, breast cancer, ovarian cancer, prostate cancer, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinomas, cystadenocarcinoma, medullary carcinoma, bronchogenic carcinoma, renal cell carcinoma, hepatoma, bile duct carcinoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilms' tumor, cervical cancer, testicular tumor, lung carcinoma, small cell lung carcinoma, non-small cell lung carcinoma, bladder carcinoma, epithelial carcinoma, glioma, astrocytoma, medulloblastoma, craniopharyngioma, ependymoma, pinealoma, hemangioblastoma, acoustic neuroma, oligodendroglioma, meningioma, melanoma, neuroblastoma, retinoblastoma, acute lymphocytic leukemia, lymphocytic leukemia, large granular lymphocytic leukemia, acute myelocytic leukemia, chronic leukemia, polycythemia vera, Hodgkin's lymphoma, non-Hodgkin's lymphoma, multiple myeloma, Waldenstrobm's macroglobulinemia, heavy chain disease, lymphoblastic leukemia, T-cell leukemia, T-lymphocytic leukemia, T-lymphoblastic leukemia, B cell leukemia, B-lymphocytic leukemia, mixed cell leukemias, myeloid leukemias, myelocytic leukemia, myelogenous leukemia, neutrophilic leukemia, eosinophilic leukemia, monocytic leukemia, myelomonocytic leukemia, Naegeli-type myeloid leukemia, nonlymphocytic leukemia, osteosarcoma, promyelocytic leukemia, non-small cell lung cancer, epithelial lung carcinoma, pancreatic carcinoma, pancreatic ductal adenocarcinoma, glioblastoma, metastatic breast cancer, melanoma, and prostate cancer.

10. The method of claim 4 , wherein the cell proliferation disorder is a cancer selected from the group consisting of osteosarcoma, promyelocytic leukemia, non-small cell lung cancer, epithelial lung carcinoma, pancreatic carcinoma, pancreatic ductal adenocarcinoma, glioblastoma, metastatic breast cancer, melanoma, and prostate cancer.

11. A method of inhibiting angiogenesis, comprising administering to a subject in need of such treatment an effective amount of a compound or pharmaceutically acceptable salt thereof according to claim 1 .

12. The compound or pharmaceutically acceptable salt thereof of claim 1 , wherein the compound is the following compound:

13. The compound or pharmaceutically acceptable salt thereof of claim 1 , wherein the compound is the following compound:

14. The compound or pharmaceutically acceptable salt thereof of claim 1 , wherein the compound is the following compound:

15. The compound or pharmaceutically acceptable salt thereof of claim 1 , wherein the compound is the following compound:

16. The compound or pharmaceutically acceptable salt thereof of claim 1 , wherein the pharmaceutically acceptable salts of the compounds of the following formula:

are selected from the group consisting of sulfate, pyrosulfate, bisulfate, sulfite, bisulfite, phosphate, monohydrogenphosphate, dihydrogenphosphate, metaphosphate, pyrophosphate, chloride, bromide, iodide, acetate, propionate, decanoate, caprylate, acrylate, formate, isobutyrate, caproate, heptanoate, propiolate, oxalate, malonate, succinate, suberate, sebacate, fumarate, maleate, butyne-1,4-dioate, hexyne-1,6-dioate, benzoate, chlorobenzoate, methylbenzoate, dinitrobenzoate, hydroxybenzoate, methoxybenzoate, phthalate, sulfonate, xylenesulfonate, phenylacetate, phenylpropionate, phenylbutyrate, citrate, lactate, gamma-hydroxybutyrate, glycolate, tartrate, methanesulfonate, propanesulfonate, naphthalene-1-sulfonate, naphthalene-2-sulfonate, and mandelate salts.

17. A pharmaceutical composition according to claim 2 comprising a pharmaceutically acceptable carrier.

18. The compound or pharmaceutically acceptable salt thereof of claim 1 , wherein the compound is selected from the group consisting of the following compounds:

19. The compound or pharmaceutically acceptable salt thereof of claim 1 , wherein the compound is selected from the group consisting of the following compounds:

20. The method of claim 4 , wherein the compound administered is the following compound:

or a pharmaceutically acceptable salt thereof.

21. The method of claim 7 , wherein the compound administered is the following compound:

or a pharmaceutically acceptable salt thereof.

22. The method of claim 9 , wherein the compound administered is the following compound:

or a pharmaceutically acceptable salt thereof.

23. The method of claim 10 , wherein the compound administered is the following compound:

Assignees

• Univ South Florida

Inventors

• Sebti Said M
• Chellappan Srikumar
• Lawrence Nicholas James

Classifications

• C07D249/14

  Nitrogen atoms · CPC title

• C07D277/42

  Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals · CPC title

• C07D317/58

  Radicals substituted by nitrogen atoms (nitro radicals C07D317/52) · CPC title

• C07D235/28

  Sulfur atoms · CPC title

• C07D213/53

  Nitrogen atoms · CPC title